Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$12.34
+1.2%
$8.99
$5.31
$12.65
$618.41M1.75424,199 shs122,259 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.16
+1.9%
$7.75
$4.78
$15.74
$477.00M3.02967,041 shs98,436 shs
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.51
+7.9%
$1.47
$1.17
$2.63
$141.82M0.2222,742 shs8,384 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$5.17
-0.3%
$6.01
$0.98
$7.44
$489.58M0.09645,045 shs62,280 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+17.78%+20.71%+39.00%+31.08%+110.54%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-4.68%-5.65%-12.69%-29.09%+22.51%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-2.78%0.00%+2.19%-21.35%-37.50%
Zura Bio Limited stock logo
ZURA
Zura Bio
-0.58%-2.26%-14.10%-13.81%+259.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$12.34
+1.2%
$8.99
$5.31
$12.65
$618.41M1.75424,199 shs122,259 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.16
+1.9%
$7.75
$4.78
$15.74
$477.00M3.02967,041 shs98,436 shs
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.51
+7.9%
$1.47
$1.17
$2.63
$141.82M0.2222,742 shs8,384 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$5.17
-0.3%
$6.01
$0.98
$7.44
$489.58M0.09645,045 shs62,280 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+17.78%+20.71%+39.00%+31.08%+110.54%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-4.68%-5.65%-12.69%-29.09%+22.51%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-2.78%0.00%+2.19%-21.35%-37.50%
Zura Bio Limited stock logo
ZURA
Zura Bio
-0.58%-2.26%-14.10%-13.81%+259.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.78
Moderate Buy$14.4417.01% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.50
Moderate Buy$19.00165.55% Upside
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.50
Moderate Buy$5.00231.13% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
2.67
Moderate Buy$10.75108.13% Upside

Current Analyst Ratings Breakdown

Latest IPHA, CYRX, FULC, and ZURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$11.00 ➝ $12.00
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $17.00
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$13.00 ➝ $15.00
4/21/2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Reiterated RatingSell (D-)
4/21/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Reiterated RatingSell (E+)
4/8/2026
Zura Bio Limited stock logo
ZURA
Zura Bio
Reiterated RatingSell (D-)
4/7/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Reiterated RatingBuy$5.00
3/30/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Initiated CoverageBuy$15.00
3/27/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingSell (D+)
3/23/2026
Zura Bio Limited stock logo
ZURA
Zura Bio
Boost Price TargetBuy$10.00 ➝ $11.00
3/20/2026
Zura Bio Limited stock logo
ZURA
Zura Bio
Lower Price TargetOutperform$16.00 ➝ $15.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M3.52N/AN/A$9.19 per share1.34
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M5.96N/AN/A$5.00 per share1.43
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$10.19M13.92N/AN/A($0.26) per share-5.81
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$1.38 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.329.13N/AN/A41.57%-7.84%-4.78%N/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%N/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$55.64MN/AN/AN/AN/AN/AN/AN/A5/13/2026 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$99.35M-$1.06N/AN/AN/AN/A-59.06%-48.04%5/7/2026 (Estimated)

Latest IPHA, CYRX, FULC, and ZURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026 TU
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$0.3492N/AN/AN/A$2.72 millionN/A
5/7/2026Q1 2026
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17N/AN/AN/AN/AN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
4/27/2026Q1 2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.31-$0.25+$0.06-$0.25N/AN/A
3/16/2026Q4 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.18-$0.49-$0.31-$0.49N/AN/A
3/3/2026Q4 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.19-$0.21-$0.02-$0.27$42.92 million$45.45 million
2/24/2026Q4 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.31-$0.31N/A-$0.31N/AN/A
2/14/2026Q4 2025
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/A-$0.18N/A-$0.18N/A$2.41 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.17
2.07
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
34.33
34.33
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/A
1.27
1.27
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
9.05
9.05

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.16%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
31.89%
Zura Bio Limited stock logo
ZURA
Zura Bio
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.20 million45.13 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10066.63 million61.97 millionOptionable
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
22093.92 million63.97 millionNot Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
394.88 million73.91 millionOptionable

Recent News About These Companies

Zura Bio (ZURA) to Release Earnings on Thursday
Zura Bio Limited Class A
Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$12.34 +0.15 (+1.22%)
As of 10:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$7.16 +0.14 (+1.92%)
As of 10:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$1.51 +0.11 (+7.86%)
As of 10:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$5.16 -0.02 (-0.29%)
As of 10:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.